NeoTargets AB
NeoTargets identifies selective and druggable cancer targets using an AI-powered in silico tool and an oncotarget discovery platform. It de-risks drug development by selecting targets with proven potency and safety, validated across translational cell models, patient samples, cancer-driving cells, and animal models. The company operates as a B2B biotech platform serving pharma and biotech researchers, and collaborates with partners such as Sprint Bioscience to advance treatments for acute myeloid leukemia. NeoTargets maintains an in-house pipeline for early-stage drug development in multiple myeloma and glioblastoma, and has identified targets across hundreds of cancer subtypes using its proprietary tools. The focus is on accelerating time-to-market, improving success rates, and expanding potential market opportunities through rigorous validation and translational science.
NeoTargets AB
NeoTargets identifies selective and druggable cancer targets using an AI-powered in silico tool and an oncotarget discovery platform. It de-risks drug development by selecting targets with proven potency and safety, validated across translational cell models, patient samples, cancer-driving cells, and animal models. The company operates as a B2B biotech platform serving pharma and biotech researchers, and collaborates with partners such as Sprint Bioscience to advance treatments for acute myeloid leukemia. NeoTargets maintains an in-house pipeline for early-stage drug development in multiple myeloma and glioblastoma, and has identified targets across hundreds of cancer subtypes using its proprietary tools. The focus is on accelerating time-to-market, improving success rates, and expanding potential market opportunities through rigorous validation and translational science.